These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 16679518)

  • 21. Biological and immunological characterization of recombinant Yellow Fever 17D viruses expressing a Trypanosoma cruzi Amastigote Surface Protein-2 CD8+ T cell epitope at two distinct regions of the genome.
    Nogueira RT; Nogueira AR; Pereira MC; Rodrigues MM; Galler R; Bonaldo MC
    Virol J; 2011 Mar; 8():127. PubMed ID: 21418577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E.
    Co MD; Terajima M; Cruz J; Ennis FA; Rothman AL
    Virology; 2002 Feb; 293(1):151-63. PubMed ID: 11853408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-Function of the Yellow Fever Virus Envelope Protein: Analysis of Antibody Epitopes.
    Davis EH; Barrett ADT
    Viral Immunol; 2020; 33(1):12-21. PubMed ID: 31682201
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a Bicistronic Yellow Fever Live Attenuated Vaccine with Reduced Neurovirulence and Viscerotropism.
    Wang HJ; Guo Y; He MJ; Liu ZY; Ye Q; Huang XY; Deng YQ; Li XF; Qin CF
    Microbiol Spectr; 2022 Oct; 10(5):e0224622. PubMed ID: 35980184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the nucleotide and deduced amino acid sequences of the envelope protein genes of the wild-type French viscerotropic strain of yellow fever virus and the live vaccine strain, French neurotropic vaccine, derived from it.
    Jennings AD; Whitby JE; Minor PD; Barrett AD
    Virology; 1993 Feb; 192(2):692-5. PubMed ID: 8421909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development.
    Gaspar LP; Mendes YS; Yamamura AM; Almeida LF; Caride E; Gonçalves RB; Silva JL; Oliveira AC; Galler R; Freire MS
    J Virol Methods; 2008 Jun; 150(1-2):57-62. PubMed ID: 18420285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Completed sequences analysis on the Chinese attenuated yellow fever 17D vaccine strain and the WHO standard yellow fever 17D vaccine strain].
    Li J; Yu YX; Dong GM
    Zhongguo Yi Miao He Mian Yi; 2009 Apr; 15(2):145-51. PubMed ID: 20077661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of three H-2K(d) restricted CTL epitopes of NS4A and NS4B protein from Yellow fever 17D vaccine.
    Zhang W; Li X; Lin Y; Tian D
    J Virol Methods; 2013 Feb; 187(2):304-13. PubMed ID: 23123122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone.
    Jiang X; Dalebout TJ; Lukashevich IS; Bredenbeek PJ; Franco D
    J Gen Virol; 2015 Apr; 96(Pt 4):804-814. PubMed ID: 25516543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of monoclonal antibodies that distinguish between 17D-204 and other strains of yellow fever virus.
    Barrett AD; Mathews JH; Miller BR; Medlen AR; Ledger TN; Roehrig JT
    J Gen Virol; 1990 Jan; 71 ( Pt 1)():13-8. PubMed ID: 1689367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Construction and biological characterization of artificial recombinants between a wild type flavivirus (Kunjin) and a live chimeric flavivirus vaccine (ChimeriVax-JE).
    Pugachev KV; Schwaiger J; Brown N; Zhang ZX; Catalan J; Mitchell FS; Ocran SW; Rumyantsev AA; Khromykh AA; Monath TP; Guirakhoo F
    Vaccine; 2007 Sep; 25(37-38):6661-71. PubMed ID: 17693000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Construction of recombinant yellow fever virus 17D containing 2A fragment as a vaccine vector].
    Xiaowu P; Fu WC; Guo YH; Zhang LS; Xie TP; Xinbin G
    Sheng Wu Gong Cheng Xue Bao; 2006 May; 22(3):492-8. PubMed ID: 16755933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Examination of the immunological relationships between flaviviruses using yellow fever virus monoclonal antibodies.
    Gould EA; Buckley A; Cammack N; Barrett AD; Clegg JC; Ishak R; Varma MG
    J Gen Virol; 1985 Jul; 66 ( Pt 7)():1369-82. PubMed ID: 2410549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The yellow fever 17D virus as a platform for new live attenuated vaccines.
    Bonaldo MC; Sequeira PC; Galler R
    Hum Vaccin Immunother; 2014; 10(5):1256-65. PubMed ID: 24553128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Japanese encephalitis virus/yellow fever virus chimera is safe and confers full protection against yellow fever virus in intracerebrally challenged mice.
    Yang H; Yang H; Li Z; Liu L; Wang W; He T; Fan F; Sun Y; Liu J; Li Y; Zeng X
    Vaccine; 2018 Apr; 36(18):2450-2455. PubMed ID: 29580643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Yellow fever virus envelope protein has two discrete type-specific neutralizing epitopes.
    Ryman KD; Ledger TN; Weir RC; Schlesinger JJ; Barrett AD
    J Gen Virol; 1997 Jun; 78 ( Pt 6)():1353-6. PubMed ID: 9191929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity.
    Monath TP; Lee CK; Julander JG; Brown A; Beasley DW; Watts DM; Hayman E; Guertin P; Makowiecki J; Crowell J; Levesque P; Bowick GC; Morin M; Fowler E; Trent DW
    Vaccine; 2010 May; 28(22):3827-40. PubMed ID: 20347059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program.
    Collaborative Group for Studies with Yellow Fever Vaccine
    Vaccine; 2007 Apr; 25(16):3118-23. PubMed ID: 17316925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amino acid substitution(s) in the stem-anchor region of langat virus envelope protein attenuates mouse neurovirulence.
    Holbrook MR; Ni H; Shope RE; Barrett AD
    Virology; 2001 Jul; 286(1):54-61. PubMed ID: 11448158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil.
    Engel AR; Vasconcelos PF; McArthur MA; Barrett AD
    Vaccine; 2006 Apr; 24(15):2803-9. PubMed ID: 16464518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.